Pfizer Inc. (PFE) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2024)
PFE's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
By Geography
PFE Revenue Analysis (2014–2025)
As of March 2, 2026, Pfizer Inc. (PFE) generated trailing twelve-month (TTM) revenue of $62.58 billion, reflecting slight decline in growth of -1.2% year-over-year. The most recent quarter (Q4 2025) recorded $17.56 billion in revenue, up 5.4% sequentially.
Looking at the longer-term picture, PFE's 5-year compound annual growth rate (CAGR) stands at +8.5%, indicating steady revenue expansion. The company achieved its highest annual revenue of $100.33 billion in 2022.
Revenue diversification analysis shows PFE's business is primarily driven by Biopharma Segment (100%). With over half of revenue concentrated in Biopharma Segment, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including MRK (+1.3% YoY), GSK (+1.8% YoY), and SNY (+8.9% YoY), PFE has underperformed the peer group in terms of revenue growth. Compare PFE vs MRK →
Peer Comparison
Compare PFE's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| PFECurrent | $62.6B | -1.2% | +8.5% | 24.7% | |
| MRK | $65.0B | +1.3% | +9.4% | 41.2% | |
| GSK | $32.0B | +1.8% | +5.6% | 21.9% | |
| SNY | $46.7B | +8.9% | +4.6% | 13.6% | |
| GRFS | $7.2B | +7.3% | +7.2% | 16.5% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $62.58B | -1.6% | $44.01B | 70.3% | $15.44B | 24.7% |
| 2024 | $63.63B | +6.8% | $41.85B | 65.8% | $16.48B | 25.9% |
| 2023 | $59.55B | -40.6% | $30.34B | 50.9% | $5.29B | 8.9% |
| 2022 | $100.33B | +23.4% | $62.09B | 61.9% | $37.55B | 37.4% |
| 2021 | $81.29B | +95.2% | $46.88B | 57.7% | $20.79B | 25.6% |
| 2020 | $41.65B | +1.2% | $29.88B | 71.7% | $9.09B | 21.8% |
| 2019 | $41.17B | -23.3% | $28.55B | 69.3% | $7.51B | 18.2% |
| 2018 | $53.65B | +2.1% | $37.64B | 70.2% | $15.29B | 28.5% |
| 2017 | $52.55B | -0.5% | $36.77B | 70.0% | $14.39B | 27.4% |
| 2016 | $52.82B | +8.1% | $36.87B | 69.8% | $14.27B | 27.0% |
See PFE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PFE Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare PFE vs AGIO
See how PFE stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is PFE's revenue growth accelerating or slowing?
PFE revenue growth slowed to -1.2%, below the 5-year CAGR of +8.5%. TTM revenue is $62.6B. The deceleration marks a shift from historical growth rates.
What is PFE's long-term revenue growth rate?
Pfizer Inc.'s 5-year revenue CAGR of +8.5% reflects the variable expansion pattern. Current YoY growth of -1.2% is near this long-term average.
How is PFE's revenue distributed by segment?
PFE reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.